These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
276 related articles for article (PubMed ID: 15032727)
1. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Underiner TL; Ruggeri B; Gingrich DE Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727 [TBL] [Abstract][Full Text] [Related]
2. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Takahashi S Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231 [TBL] [Abstract][Full Text] [Related]
3. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis. Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249 [TBL] [Abstract][Full Text] [Related]
4. [VEGF-receptor inhibitors for anti-angiogenesis]. Shibuya M Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004 [TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. Veeravagu A; Hsu AR; Cai W; Hou LC; Tse VC; Chen X Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):59-71. PubMed ID: 18221053 [TBL] [Abstract][Full Text] [Related]
6. Antiangiogenic agents: an update on small molecule VEGFR inhibitors. Schenone S; Bondavalli F; Botta M Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703 [TBL] [Abstract][Full Text] [Related]
7. Vascular endothelial growth factor (VEGF) inhibition by small molecules. Ahmed SI; Thomas AL; Steward WP J Chemother; 2004 Nov; 16 Suppl 4():59-63. PubMed ID: 15688612 [TBL] [Abstract][Full Text] [Related]
8. Vascular endothelial growth factor (VEGF) as a target of bevacizumab in cancer: from the biology to the clinic. Ranieri G; Patruno R; Ruggieri E; Montemurro S; Valerio P; Ribatti D Curr Med Chem; 2006; 13(16):1845-57. PubMed ID: 16842197 [TBL] [Abstract][Full Text] [Related]
9. Molecular design and clinical development of VEGFR kinase inhibitors. Zhong H; Bowen JP Curr Top Med Chem; 2007; 7(14):1379-93. PubMed ID: 17692027 [TBL] [Abstract][Full Text] [Related]
10. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity. Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466 [TBL] [Abstract][Full Text] [Related]
12. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Ruggeri B; Singh J; Gingrich D; Angeles T; Albom M; Yang S; Chang H; Robinson C; Hunter K; Dobrzanski P; Jones-Bolin S; Pritchard S; Aimone L; Klein-Szanto A; Herbert JM; Bono F; Schaeffer P; Casellas P; Bourie B; Pili R; Isaacs J; Ator M; Hudkins R; Vaught J; Mallamo J; Dionne C Cancer Res; 2003 Sep; 63(18):5978-91. PubMed ID: 14522925 [TBL] [Abstract][Full Text] [Related]
13. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future. Sharma PS; Sharma R; Tyagi T Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218 [TBL] [Abstract][Full Text] [Related]
14. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors. Lacal PM; Graziani G Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor-associated tyrosine kinase activity with SU5416 blocks sprouting in the microvascular endothelial cell spheroid model of angiogenesis. Haspel HC; Scicli GM; McMahon G; Scicli AG Microvasc Res; 2002 May; 63(3):304-15. PubMed ID: 11969307 [TBL] [Abstract][Full Text] [Related]
16. Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases. Shibuya M J Biochem; 2013 Jan; 153(1):13-9. PubMed ID: 23172303 [TBL] [Abstract][Full Text] [Related]
17. DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Li MY; Lv YC; Tong LJ; Peng T; Qu R; Zhang T; Sun YM; Chen Y; Wei LX; Geng MY; Duan WH; Xie H; Ding J Acta Pharmacol Sin; 2016 Mar; 37(3):398-407. PubMed ID: 26806300 [TBL] [Abstract][Full Text] [Related]
18. New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. Bold G; Altmann KH; Frei J; Lang M; Manley PW; Traxler P; Wietfeld B; Brüggen J; Buchdunger E; Cozens R; Ferrari S; Furet P; Hofmann F; Martiny-Baron G; Mestan J; Rösel J; Sills M; Stover D; Acemoglu F; Boss E; Emmenegger R; Lässer L; Masso E; Roth R; Schlachter C; Vetterli W J Med Chem; 2000 Jun; 43(12):2310-23. PubMed ID: 10882357 [TBL] [Abstract][Full Text] [Related]
19. Small molecule inhibitors of KDR (VEGFR-2) kinase: an overview of structure activity relationships. Boyer SJ Curr Top Med Chem; 2002 Sep; 2(9):973-1000. PubMed ID: 12171566 [TBL] [Abstract][Full Text] [Related]
20. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Pallares J; Rojo F; Iriarte J; Morote J; Armadans LI; de Torres I Histol Histopathol; 2006 Aug; 21(8):857-65. PubMed ID: 16691538 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]